enGene announced 54% complete response rate in LEGEND pivotal cohort and plans to initiate a Biologics License Application for detalimogene in the second half of 2026 pending FDA engagement. The company reduced workforce by 50% to preserve $285 million in cash and focus on regulatory and precommercial activities.